These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

550 related articles for article (PubMed ID: 19584324)

  • 41. JAK2 inhibitors for myeloproliferative neoplasms: what is next?
    Bose P; Verstovsek S
    Blood; 2017 Jul; 130(2):115-125. PubMed ID: 28500170
    [TBL] [Abstract][Full Text] [Related]  

  • 42. JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia.
    Campiotti L; Appio L; Solbiati F; Ageno W; Venco A
    Leuk Res; 2009 Nov; 33(11):e212-3. PubMed ID: 19589593
    [No Abstract]   [Full Text] [Related]  

  • 43. Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation.
    Potenza L; Volzone F; Riva G; Soverini S; Martinelli S; Iacobucci I; Gnani A; Barozzi P; Forghieri F; Morselli M; Zanetti E; Maccaferri M; Baccarani M; Martinelli G; Torelli G; Luppi M
    Br J Haematol; 2009 Jul; 146(2):227-30. PubMed ID: 19545285
    [No Abstract]   [Full Text] [Related]  

  • 44. Postimatinib therapy emergence of a new JAK2V617F clone and subsequent development of overt polycythemia vera in a patient with chronic myelogenous leukaemia.
    Tefferi A; Levitt R; Lasho TL; Knudson RA; Ketterling RP
    Eur J Haematol; 2010 Jul; 85(1):86-7. PubMed ID: 20408872
    [No Abstract]   [Full Text] [Related]  

  • 45. [Role of the activating mutation Val617Phe of Janus kinase 2 gene in myeloproliferative diseases and significance of its detection].
    Andrikovics H; Szilvási A; Meggyesi N; Király V; Halm G; Lueff S; Nahajevszky S; Mikala G; Sipos A; Lovas N; Csukly Z; Mátrai Z; Tamáska J; Tordai A; Masszi T
    Orv Hetil; 2007 Feb; 148(5):203-10. PubMed ID: 17344140
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Status and perspectives on chronic myeloproliferative neoplasm treatment].
    Ocias LF; Holmström MO; Riley CH; Andersen CL; Rønnov-Jessen D; Starklint J; Frederiksen M; Steffensen MS; Bjerrum OW; Farmer S; Mourits-Andersen T; Hasselbalch HC; Larsen TS
    Ugeskr Laeger; 2015 May; 177(19):. PubMed ID: 25967090
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Physiopathology, diagnosis and treatment of chronic myeloproliferative diseases: discussion].
    Usui N; Miyamura K; Arai A; Motomura S; Yokoyama M
    Nihon Naika Gakkai Zasshi; 2007 Jul; 96(7):1434-55. PubMed ID: 17682432
    [No Abstract]   [Full Text] [Related]  

  • 48. JAK-mutant myeloproliferative neoplasms.
    Levine RL
    Curr Top Microbiol Immunol; 2012; 355():119-33. PubMed ID: 21823028
    [TBL] [Abstract][Full Text] [Related]  

  • 49. JAK2 mutations in myeloproliferative disorders.
    Tefferi A; Lasho TL; Gilliland G
    N Engl J Med; 2005 Sep; 353(13):1416-7; author reply 1416-7. PubMed ID: 16192494
    [No Abstract]   [Full Text] [Related]  

  • 50. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.
    Levine RL; Pardanani A; Tefferi A; Gilliland DG
    Nat Rev Cancer; 2007 Sep; 7(9):673-83. PubMed ID: 17721432
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeted cancer therapy: promise and reality.
    Klein S; Levitzki A
    Adv Cancer Res; 2007; 97():295-319. PubMed ID: 17419951
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia.
    Winton EF; Kota V
    Future Oncol; 2017 Feb; 13(5):395-407. PubMed ID: 27785927
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Management strategy for BCR-ABL negative myeloproliferative neoplasms].
    Gotoh A; Komatsu N
    Rinsho Ketsueki; 2014 Jan; 55(1):56-65. PubMed ID: 24492037
    [No Abstract]   [Full Text] [Related]  

  • 54. [Successful treatment with dasatinib for polycythemia vera patient emerging BCR-ABL positive clone during 13 years of treatment].
    Takizawa M; Yokohama A; Sekigami T; Koiso H; Ishizaki T; Mitsui T; Ogawa Y; Saitoh T; Handa H; Tsukamoto N; Murakami H; Nojima Y
    Rinsho Ketsueki; 2014 Jun; 55(6):687-91. PubMed ID: 24975338
    [TBL] [Abstract][Full Text] [Related]  

  • 55. AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders.
    Dawson MA; Curry JE; Barber K; Beer PA; Graham B; Lyons JF; Richardson CJ; Scott MA; Smyth T; Squires MS; Thompson NT; Green AR; Wallis NG
    Br J Haematol; 2010 Jul; 150(1):46-57. PubMed ID: 20507304
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chromosome abnormalities in the myeloproliferative disorders.
    Dewald GW; Wright PI
    Semin Oncol; 1995 Aug; 22(4):341-54. PubMed ID: 7638632
    [No Abstract]   [Full Text] [Related]  

  • 57. Jak-2 positive myeloproliferative neoplasms.
    Muxí PJ; Oliver AC
    Curr Treat Options Oncol; 2014 Jun; 15(2):147-56. PubMed ID: 24627006
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Janus kinase 2 inhibitors in myeloproliferative disorders.
    Lucia E; Recchia AG; Gentile M; Bossio S; Vigna E; Mazzone C; Madeo A; Morabito L; Gigliotti V; De Stefano L; Caruso N; Servillo P; Franzese S; Bisconte MG; Gentile C; Morabito F
    Expert Opin Investig Drugs; 2011 Jan; 20(1):41-59. PubMed ID: 21128825
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical applications of molecular haematology: JAK2 in myeloproliferative disorders.
    Agarwal MB
    J Assoc Physicians India; 2007 Jul; 55():507-10. PubMed ID: 17907502
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
    Pikman Y; Levine RL
    Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.